Bionomics Limited operates within the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Bionomics Limited with three other companies in this sector in Australia: Pharmaxis Ltd (2017 sales of 17.64 million Australian Dollars [US$13.51 million] of which 77% was Bronchitol and Aridol), Tempo Australia Limited (18.51 million Australian Dollars [US$14.17 million] ), and Clinuvel Pharmaceuticals Limited (17.03 million Australian Dollars [US$13.04 million] of which 100% was Biotechnology).

Sales Analysis. During the year ended June of 2017, sales at Bionomics Limited were A$18.61 million (US$14.25 million). This is an increase of 128.5% versus 2016, when the company's sales were A$8.14 million. Sales of Drug Discovery and Development saw an increase of 199.4% in 2017, from A$5.48 million to A$16.42 million. Not all segments of Bionomics Limited experienced an increase in sales in 2017: sales of Contract Services fell 13.3% to A$5.75 million.